RA Capital Funds, Directors Buy $8.76M in Mineralys Therapeutics Stock
Summary
RA Capital Healthcare Fund LP and affiliated entities, including directors Peter Kolchinsky and Rajeev Shah, made significant open market purchases of Mineralys Therapeutics common stock totaling $8.76 million.
Key Events
-
Significant Insider Purchase
RA Capital Healthcare Fund LP and its affiliates, including directors Peter Kolchinsky and Rajeev Shah, acquired 369,000 shares of Mineralys Therapeutics common stock.
-
Substantial Investment Value
The open market purchases totaled $8,762,797, executed between March 27 and March 30, 2026, at prices ranging from $23.67 to $24.16 per share.
-
Institutional Confidence
This transaction by a major institutional investor with board representation indicates strong belief in the company's prospects, particularly following the recent FDA NDA acceptance for lorundrostat.
Analysis
This substantial open market purchase by RA Capital, a major institutional investor with board representation, signals strong conviction in Mineralys Therapeutics. The acquisition of nearly $8.8 million in shares, representing a notable percentage of the company's market capitalization, suggests that key insiders associated with the fund see significant value at current price levels. This comes after the company's recent 10-K filing confirmed FDA acceptance of its NDA for lorundrostat, with a PDUFA date set for December 2026, indicating confidence ahead of a critical regulatory milestone.
At the time of this filing, MLYS was trading at $28.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $10.44 to $47.65. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.